Alemtuzumab in the Long-Term Treatment of Relapsing-Remitting Multiple Sclerosis: An Update on the Clinical Trial Evidence and Data From the Real World
Therapeutic Advances in Neurological Disorders - United Kingdom
doi 10.1177/1756285617722706
Full Text
Open PDFAbstract
Available in full text
Date
August 4, 2017
Authors
Publisher
SAGE Publications